Waning of post-vaccination neutralizing antibody responses against SARS-CoV-2, a systematic literature review and meta-analysis

Introduction

COVID-19 vaccines continue to effectively protect against severe disease and death caused by SARS-CoV-2 despite continuous viral evolution and waning immunity^1–3. However, vaccine effectiveness against SARS-CoV-2 transmission, infection, and symptomatic disease has declined, and immunity against the Wuhan Index strain, either elicited by vaccination or previous infection, shows little protection against infection with Omicron-related viral variants^2–4. Thus hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination) involving infections with more recent viral variants is increasingly relevant. Clinical studies are imperative for assessing the impact of novel viral variants on vaccine performance and understanding the waning of protection after vaccination and/or infection, but these studies demand significant time. While laboratory data, such as neutralizing antibody titers, can be generated and shared much more quickly thereby potentially informing vaccine policy when clinical data are lacking, single studies often lack the power to provide sound and robust conclusions regarding complex biological functions such as antibody waning⁵. Meta-analysis of data across studies can increase power and can evaluate impact of different immunological factors, including number of doses and effects of hybrid immunity.

We systematically reviewed the evidence of post-vaccination neutralization antibody titers against the Index strain and Omicron BA.1 over time and compared the degree of waning after the last dose between primary and booster vaccination and between infection-naïve and hybrid-immune participants.

Methods

Results

We screened titles and abstracts from 8418 articles, of which 347 underwent full-text review and 26 were eligible for analyses (Figure 1). Abstracted neutralization titers and relevant cohort characteristics including study population, number of doses, vaccine product, and infecting strain are provided in Supplementary appendix 1.

• Download figure
• Open in new tab

Figure 1: Study identification and Selection.

Five strata had six or more cohorts for meta-analyses: 1) infection-naïve, post-primary vaccination titers against the Index strain (n= 18 cohorts); 2) infection-naïve, post-boost vaccination titers against the Index strain (n= 18); 3) infection-naïve, post-boost vaccination titers against Omicron BA.1 (n= 15); 4) hybrid-immune, post-primary vaccination against the Index strain (n= 8); and 5) hybrid-immune, post-primary vaccination against Omicron BA.1 (n= 6; Figure 1). Too few (≤ 3 cohorts) assessed hybrid-immune, post-booster vaccination titers, vaccination with four or more doses, or vaccination with variant-adapted vaccines, and were therefore not meta-analyzed. Among hybrid-immune cohorts, all studies evaluated infections occurring prior to the last dose except one, which provided data after breakthrough infection but was excluded from meta-analysis because sampling time-points were unclear⁸]. All hybrid-immunity cohorts were from pre-Omicron infections so we could not assess impact of variant-specific effects on hybrid-immunity.

There was wide heterogeneity in peak GMTs across studies within strata, for example ranging between 101 and 4096 among infection-naïve participants boosted with mRNA vaccines (Figure 2b, supplementary appendix 1), resulting in wide confidence intervals of meta-analyses. Average peak GMTs differed between strata, with highest average GMTs observed against the Index strain in hybrid-immune post-primary participants and lowest against Omicron BA.1 in infection-naïve post-boost participants (Table 1, Figure 2). As expected, average peak titers post-vaccination were higher in subjects with an infection history compared to naïve subjects and titers against Omicron BA.1 were generally lower than those against the Index strain. Mean peak titers were significantly higher for mRNA vaccines compared to other vaccine platforms; however, few studies evaluated inactivated (n=3 cohorts from 3 studies^9–11) or viral vector vaccines (n= 8 cohorts from 6 studies^12–17), and only two of these studies provide direct comparisons to other platforms^12,13.

• Download figure
• Open in new tab

Figure 2: Neutralizing antibody titers over time since last vaccination against the Index strain or Omicron BA.1 in infection-naïve or hybrid-immune participants after primary or booster vaccination.

Rates of waning against the Index strain (A – C) and against Omicron BA.1 (D and E) are shown stratified by prior infection status and dose. Lines connecting data points represent individual cohorts, color coded by vaccine platform. Bold red lines represent average declines from meta-regression for each stratum; shaded area represents 95% confidence intervals of GMT over time. Abbreviations: GMT, geometric mean titer; CI, confidence interval; Index, SARS-CoV-2 Wuhan-like including D614G-strains; +mRNA, heterologous vaccine regimen involving at least one mRNA-vaccine dose; -mRNA, heterologous vaccine regimen involving no mRNA-vaccine dose.

Average neutralization titers declined from month 1 to 6 in all five strata, ranging from 3.7-fold (95%CI 1.7-7.9) against the Index strain in hybrid-immune participants post-primary to 5.9 (95% CI 3.8-9.0) against Omicron BA.1 in infection-naïve boosted participants (Table 1, Figure 2), but the declines were not statistically significantly different between strata (p= .67). The rate of waning in the first 6 months appeared linear in all five strata (all p > 0.15 for quadratic term), but most cohorts (39 of 48; 81.2%) provided data for only two time-points and no eligible studies had more than three time-points. Although declines in neutralizing antibodies cross-reactive to Omicron BA.1 appeared to be greater than declines of Index-specific responses in both infection-naïve and hybrid-immune cohorts (5.0-to 5.9-fold reductions vs. 3.7-to 3.8-fold, respectively), they were not statistically significant (p= .22), nor were rates of decline statistically different for any covariate evaluated (all p > .17).

Neutralization titers declined in all cohorts except two (Figure 2 panel B), that were from a single study¹² that assessed titers at shorter follow-up times (months 1 and 3), among participants vaccinated with a vector vaccine (of five comparable cohorts that evaluated vector vaccines). Statistically significant increases in neutralizing antibody (GMTs from 1090.5 to 1444.3) against the Index strain were observed in one cohort that received a heterologous booster with Ad26.CoV2.S as a third dose after two doses of mRNA vaccine in infection-naïve participants. There was no change in a second cohort that received two doses of Ad26.CoV2.S (GMTs 122.8 and 138.2); however, titers against Omicron BA.1 declined in both (358.9 to 123.0 and 26.9 to 11.2, respectively; both p < .05) and significant declines were observed for two other cohorts in the same study that received either mRNA vaccines or heterologous vaccination with Ad26.CoV2.S as a first dose.

Discussion

Through a systematic literature review and meta-analysis, we found neutralizing antibodies declined after COVID-19 vaccination from months one to six ranging from 3.7-fold to 5.9-fold when evaluating post-primary or first booster against either the Index strain or Omicron BA.1. Waning rates were generally similar after primary or first booster regimens, and between infection-naïve and previously infected cohorts. Declines of neutralizing antibodies cross-reactive to Omicron BA.1 were greater than declines of Index-specific responses, both in infection-naïve and hybrid-immune cohorts, though this difference was not statistically significant. Only three studies evaluated a second booster; two reported no significant differences in waning kinetics between first and second booster^26,27 and one reported slightly enhanced antibody durability after the second booster, but the second booster cohort was small (n=7)²¹. Because waning was similar after primary and first booster doses, degree of waning with subsequent doses is also expected to be similar. However, data to assess long-term waning, such as 12 months after the last vaccine dose, were unavailable, complicated both by needing to wait that long and by study subjects getting revaccinated before that time. As duration between vaccinations increases, this may be addressed in future studies. These waning rates could be used to predict waning for future relevant scenarios and adapt vaccination strategies accordingly.

Declines in neutralization titers were observed in all but three infection-naïve cohorts evaluated. One cohort that received a heterologous boost regimen (inactivated prime followed by a vector boost) was followed for 3 months and no change in titers was observed⁹. However, overall titers were low throughout. Two additional cohorts, one vaccinated with two doses of vector vaccine (out of five available vector-immunized cohorts) and one with a heterologous regimen (mRNA prime followed by a vector boost) had titers that increased against the Index strain through month 3 (longer follow-up was not conducted)¹². Titers against Omicron BA.1 declined in these cohorts indicating that no undetected breakthrough infection occurred driving these titer increases. Interestingly, these three exceptional cohorts all received a vector vaccine as the last dose and hence it can be speculated that vector-mediated immunization might cause more durable antibody responses early after immunization/booster. On the other hand, studies with longer-term follow-up support overall comparable rates of waning across vaccine platforms beyond three months after the last dose, which might be explained by full clearance of the vector and any benefit it might add. More studies are needed to address this important observation and explore the potential role vector vaccines could play in enhancing durable immune responses. While we and others have shown that vector vaccines are generally less immunogenic compared to mRNA vaccines, heterologous regimens combining mRNA and vector vaccines have been shown to elicit immune responses comparable to mRNA vaccinations alone^13,29. Hence, boosters with vector vaccines in mRNA-primed (or already mRNA-boosted) participants could elicit the highest and most durable immune responses. This has been shown by Lyke et al. who observed that titers were more stable in subjects who received an mRNA prime followed by a vector boost than subjects who received three doses of mRNA vaccine¹². We identified four additional cohorts (from three studies) evaluating hybrid-immune subjects that did not show a significant decline of titers in the observed period, and two of these cohorts were followed for more than six months post-last vaccine dose^8,16,30. However, two of the studies did not investigate breakthrough infections after the last vaccine dose^8,30. Breakthrough infections in even a small proportion of the subjects can have a large impact on the overall GMT because the impact of these few infections on the overall GMT of a group can be large. Therefore, these studies should be considered with caution. Still, one study on hybrid-immune subjects that ruled out breakthrough infections after the last vaccine dose showed stable titers over a three-month period¹⁶ which supports other observations that hybrid-immunity might have the potential to stabilize antibody titers at least temporarily²¹.

Neutralizing antibody titers can support and complement clinical vaccine effectiveness data as they correlate well with protection against infection and mild disease. Even if neutralizing antibodies fail to hinder initial infection and symptomatic disease, they will limit initial viral load and thus mitigate disease progression, so they correlate also with protection against severe disease. This can be seen by the see-saw pattern of COVID-19 vaccine effectiveness against severe disease which was similar to titers peaking in the first weeks after each dose and falling thereafter until the next dose³. However, the observed larger declines in titers against Omicron relative to the Index strain may correlate less well to clinical vaccine effectiveness against severe disease, which shows less waning than VE against symptomatic disease and infection. This supports that protection is aided by additional factors such as cellular immunity, which has gained increasing recognition for its importance for protection against severe disease¹⁸. While no precise correlates of protection are defined for neutralizing antibodies, an understanding of overall titers and waning rates will allow us to predict how fast protection against infection and mild disease will decline and whether this might differ by vaccine type, regimen, infection history or characteristics such as sex, age, or comorbidities to inform vaccine policy, including the time interval when additional vaccine doses should be given.

But even studying neutralization titers takes time; very few longitudinal studies with data against Omicron subvariants other than for BA.1 were available at the time of this review, and increasing immune escape from post-vaccination neutralizing antibody responses resulting in large proportions of participants with undetectable titers makes them difficult to evaluate, especially in infection-naïve cohorts post-primary vaccination. Indeed, available studies for newer sub-variants provide contradictory results with some observing increased rates of waning against Omicron sub-variants compared to the Index variant^19,20, some finding similar rates of waning^{21– 23}, and others reporting lower rates^24,25. More evidence is needed to determine if waning of post-vaccination neutralizing antibody titers cross-reactive to newer Omicron subvariants differs from those reactive to the Index variant or to Omicron BA.1. Such results may depend on whether the vaccine targets the emerging subvariants. We found only one study assessing waning of neutralizing antibodies after bivalent mRNA vaccination (Index plus BA.4/5 antigen), which found greater waning during the first three months against Omicron subvariants than against the Index variant²⁸, similar to our observations for monovalent Index-directed vaccines. We were also unable to assess variant-specific effects on hybrid-immunity since all hybrid-immune cohorts investigated involved pre-Omicron infections.

Our results confirm observations of superior immunogenicity of some vaccination strategies over others. We observed significant differences in overall titers by vaccine platform, with mRNA vaccines resulting in higher titers and inactivated vaccines the lowest. Importantly, waning rates were not significantly different between the platforms. These results support previous findings that both booster doses and hybrid-immunity significantly increase overall titers and titers against Omicron BA.1 are generally lower than against the Index strain^8,30–33. Importantly, these results provide evidence of a relatively constant rate of waning for the different groups included in the analysis; thus, individuals immunized with a less immunogenic primary regimen are likely to reach non-protective antibody titers faster. This effect becomes more significant when comparing primary regimen to hybrid-immune or boosted cohorts. These results may prove informative for booster strategies, especially when vaccine supply is low or if over-immunization should be avoided because of possible imprinting and a lack of variant-adapted vaccines.

A systematic assessment of study reliability revealed that 88% of included studies had medium, low, or unclear reliability scores reflecting primarily poor reporting quality of study methods and details. While this does not necessarily translate to biased or unreliable data, the overall low-reliability scores and small percentage of studies with a high-reliability score reflects that data on neutralizing antibodies are difficult to compare across studies^4,5. This finding is further reflected by the wide confidence intervals observed in our meta-regression results. However, we included all studies meeting inclusion criteria irrespective of their reliability score for sample size reasons. A sensitivity analysis did not find an association between study results and reliability score, i.e., poorer scores were not more likely to be outliers.

In summary, neutralizing antibody titers are an important correlate of protection against infection and continued monitoring of new vaccines as they become available and new variants as they emerge will provide important alert signals and information to help guide vaccination regimens in the future. While absolute values of neutralization titers continue to vary widely between studies, this evaluation across many cohorts provides confidence that large differences in waning rates after booster doses are unlikely between vaccines used widely to date. However, significantly different baseline titers by vaccine platform and number of doses and infections means titers will drop to non-functional levels sooner for some conditions, which is particularly important for public health policymaking. Additionally, we could not evaluate the most recent conditions, and waning against Omicron sub-variants other than BA.1 might be slightly faster. This should be monitored carefully, as well as waning against clinically relevant Omicron sub-variants after variant-adapted vaccination and the impact of hybrid-immunity by Omicron sub-variants, especially in combination with variant-adapted vaccination.

Contributors

HJ and IS performed the systematic literature review, screened, and excluded studies. HJ, MK, RN and IS abstracted data from included studies. HJ and IS calculated GMT, SD, SE, and 95% CI from raw data where necessary. MDK performed the meta-analysis. HJ performed initial interpretation and wrote the manuscript. HJ and MK prepared figures. IS, VCJ, DRF, MDK, RN and MH reviewed the manuscript and supported interpretation. MH acquired funding. All authors read and revised the manuscript.

Funding

This project was funded by the Coalition for Epidemic Preparedness Innovations, grant number 138587.

Declaration of Interest

MMH and MDK report research grants from Pfizer (all paid to the institution) for unrelated projects. All other authors declare no competing interests.

Supplements

Supplementary appendix 1: Study characteristics and data from included studies

Supplementary appendix 2: Reliability assessment, individual assessment outcomes

Supplementary figure 1: Reliability assessment, summary

• Download figure
• Open in new tab

Supplementary Figure 1: Reliability assessment.

All studies that were included in the meta-analyses were assessed with a reliability score using a previously published tool⁵. Studies were considered to have high reliability if no criterion had more than a low risk score (yellow), medium reliability if no criterion was above a medium risk score (orange) and low if at least one criterion met a high risk score (red). No study met the “very high” reliability score (no criterion with risk of bias). Studies with at least one criterion that could not be assessed (e.g. no data provided or unclear), received an unclear reliability (purple). Eleven categories are assessed by the tool and assigned an independent risk score. The maximum impact a category can have is shown as “max impact” indicating the worst possible outcome for this category. The percentage of categories with a low or no risk is shown on the right, complementing the final reliability.

Supplementary figure 2: Reliability assessment, sensitivity analysis

• Download figure
• Open in new tab

Supplementary Figure 2: Reliability assessment of included studies.

Rates of waning against the Index strain (A – C) and against Omicron BA.1 (D and E) shown colored according to reliability as assessed by a previously published standardized reliability assessment tool⁵. Studies assessed as high to medium reliability are shown in grey, low reliability studies are shown in red. Studies with unclear reliability are included to “low to medium risk”. Abbreviations: GMT, geometric mean titer; Index denotes SARS-CoV-2 Wuhan-like including D614G-strains.